Ticker LaunchUplisting · AIMD
Ainos, Inc.
Formerly Ainos, Inc.; AMARILLO BIOSCIENCES INC
Ainos, Inc. (AIMD), already reporting to the SEC, moved up to Nasdaq Capital Market on Aug 10, 2022 with an offering at $4.25 per share raising $3.3M. Maxim Group was lead-left underwriter, joined by Brookline and Arcadia. Baker McKenzie advised the company and Loeb & Loeb advised the underwriters.
Ainos, Inc. is a diversified medtech company developing point-of-care testing products, low-dose interferon therapeutics and synthetic RNA-driven preventative medicine. Its testing devices include COVID-19 tests and products that detect volatile organic compounds emitted by the human body.
- Status
- Uplisting
- Ticker
- AIMD
- Exchange
- Nasdaq Capital Market
- Listed
- Aug 10, 2022
- Price
- $4.25
- Raised
- $3.3M
- Market cap at IPO price
- $82.8M
- First filed
- Apr 24, 2008
- Underwriters
- Maxim Group, Brookline and Arcadia
- Company counsel
- Baker McKenzie
- Underwriters' counsel
- Loeb & Loeb
- Sector
- Technology
- Country / state
- TX
More on this listing for subscribers
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Apr 24, 2008
- Latest amendment Aug 2, 2022
- Final prospectus (424B4) Aug 10, 2022
- All filings on EDGAR CIK 1014763
Other Technology uplistings in 2022
- mCloud Technologies Corp.MCLDP · Dec 28, 2022
- Next Technology Holding Inc.WETG · Jul 19, 2022 · $40M
- Airwa Inc.CNXA · Jun 16, 2022 · $4M
- Algorhythm Holdings, Inc.SMDM · May 25, 2022 · $4M
- Applied Digital Corp.APLD · Apr 13, 2022 · $40M
- AppTech Payments Corp.APCX · Jan 6, 2022 · $15M